Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

23
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
23
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

26
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
26

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

Deuruxolitinib: New Approval.

Clinical drug investigation·2026
Same journal

Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review.

Clinical drug investigation·2026
Same journal

Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation.

Clinical drug investigation·2026
Same journal

Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy Participants.

Clinical drug investigation·2026
Same journal

Ketamine and Evolving Neuroplasticity.

Clinical drug investigation·2026
Same journal

Amyloid-Related Imaging Abnormalities in Anti-amyloid Therapy: Clinical Implications of Kinetics for Safer Use and Risk Stratification.

Clinical drug investigation·2026
查看所有相关文章

相关实验视频

Updated: Sep 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

米托米辛内溶液:首次批准

Susan J Keam1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cdi@adis.com.

Clinical drug investigation
|August 31, 2025
PubMed
概括
此摘要是机器生成的。

现在美国批准ZUSDURITM,一种新型的水凝米托辛配方,用于通过内灌注治疗复发性低级中等风险的非肌肉侵入性膀癌 (LG- IR- NMIBC).

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.8K

相关实验视频

Last Updated: Sep 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.8K

科学领域:

  • 癌症学
  • 泌尿外科
  • 药物开发

背景情况:

  • 非肌肉侵入性膀癌 (NMIBC) 需要有效的静脉治疗.
  • 低级中等风险NMIBC (LG-IR-NMIBC) 存在特殊的治疗挑战.
  • 现有的LG-IR-NMIBC治疗方法存在局限性,需要新的方法.

研究的目的:

  • 概述了米托米辛静脉溶液 (ZUSDURITM) 的发展里程碑.
  • 突出导致LG-IR-NMIBC治疗获得FDA批准的过程.
  • 提供关于膀癌新疗法的概述.

主要方法:

  • 对米托米辛静脉溶液的发展史和临床数据的审查.
  • 对监管提交和批准过程的分析.
  • 专注于水凝配方和体内灌注输送方法.

主要成果:

  • 已开发出一种水凝配方的米托米辛静脉溶液 (ZUSDURITM).
  • 美国FDA于2025年6月批准ZUSDURITM治疗复发性LG-IR-NMIBC.
  • 这标志着这种特定的膀癌亚型的静脉注射治疗取得了重大进展.

结论:

  • 在膀癌治疗中,米托米辛溶液是显著的进步.
  • 这种水凝配方提供了一种新的药物输送方法.
  • 对于LG-IR-NMIBC复发的患者来说,FDA的批准意味着一种新的治疗选择.